Wegovy can be prescribed to adults and children over 12 who are motivated to tackle obesity or have weight-related health issues
[DOI] [PubMed] [Google Scholar] 92.Murakami M., Naraba H., Tanioka T., Semmyo N., Nakatani Y., Kojima F., Ikeda T., Fueki M., Ueno A., Oh S., et al
Wegovy and Rybelsus didnt carry these warnings until November 2024 and December 2024, respectively
It is not a dermal filler and should not be positioned as a product for volume restoration
Side Effects & Safety Considerations The adverse event profile of MOUNJARO (tirzepatide) is predominantly gastrointestinal, aligning with the incretin receptor agonist class, with frequency and severity correlating to dose and titration speed.[3][4] Most common reactions include nausea, diarrhea, vomiting, abdominal pain, constipation, dyspepsia, and decreased appetite.[3][4] These effects are typically mild-to-moderate, peak during dose escalation, and lessen over time on a stable dose.[3] If tolerability is significantly compromised, providers should consider delaying escalation or extending the current dose interval
